Razorfish: Mayer De...
Health Care: Drugs
Ariad Pharmaceuticals (ARIA: NASDAQ)
$16.62 -0.05 | -0.30%
05/20/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 16.62 |
| 52 Week High | 25.40 |
| 52 Week Low | 15.13 |
| Avg. Daily Vol. (Mil) | 3.02 |
| Beta (3 year) | 1.32 |
| Share Related Items | |
| Mkt Cap (Mil) | 3,069.56 |
| Shares Out (Mil) | 184.69 |
| Float (Mil) | 178.77 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 7.60 |
| Current Ratio | 7.80 |
| LT Debt/ Equity | 0.08 |
| Total Debt / Equity | 0.08 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 442.24 |
| Price/Book | 8.43 |
| Price/Cash Flow | -13.90 |
| Per Share Data | |
| Earnings | -1.35 |
| Sales | 0.04 |
| Book Value | 1.97 |
| Cash Flow | -1.20 |
| Business Summary | |
|---|---|
| Ariad Pharmaceuticals Inc is engaged in the discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. | |
| General Information | |
| 26 Landsdowne Street
Cambridge, MA 02139-4234 |
|
| www.ariad.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 300 | |
| CEO: Dr. Harvey J. Berger,M.D | |
| Short Interest | |
| Current Month (Mil) | 12.74 |
| Previous Month (Mil) | 10.88 |
| Short Interest Ratio (Days) | 3.90 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -50.80 |
| Return on Investments | -58.00 |
| Profitability | |
| Gross Margin | 96.10 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with ARIA
- Portfolio NameUser Type
- ProSteven Cohen - SAC Capital
- ProDaniel Loeb - Third Point
- ContributorBreakout Stocks Of The Week...
- ContributorEarnings Short Squeeze Play...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks At New 52-Week Highs...
- ContributorStocks Rising On Unusual Vo...
Latest ARIA Headlines from TheStreet
- Ariad Stock Falls On Unusually High Volume (ARIA) 05.16.13 | 12:05 pm
- 10 ASCO '13 Abstracts You Can Read Right Now 05.15.13 | 06:05 pm
- Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech 04.05.13 | 07:04 am
- Ariad CEO Strikes Back, Insists Leukemia Drug Is Fine 04.04.13 | 10:04 am
- Ariad Stock Falls On Unusually High Volume (ARIA) 04.03.13 | 02:04 pm
- The Survey Says: Ariad's Leukemia Drug Is Toxic 04.03.13 | 01:04 pm
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- Ariad Pharmaceuticals (ARIA): Drugs' Highlighted Dud Of The Day 03.28.13 | 05:03 pm
- Ariad Pharma Falls On Weak Leukemia Drug Prescriptions 03.27.13 | 12:03 pm
- Ariad Stock Falls On Unusually High Volume (ARIA) 03.25.13 | 04:03 pm
Press Releases for ARIA
- ARIAD Announces That Iclusig™ (Ponatinib) Receives Positive CHMP Opinion For Approval In The European Union - Business Wire 03.22.13 | 08:03 am
- ARIAD Announces Presentations Of Preclinical Data At American Association For Cancer Research Annual Meeting - Business Wire 03.20.13 | 07:03 am
- ARIAD To Present At Barclays Global Healthcare Conference - Business Wire 03.06.13 | 07:03 am
- ARIAD To Present At The Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.28.13 | 07:02 am
- ARIAD Reports 2012 Financial Results And Outlines Key Objectives For 2013 - Business Wire 02.25.13 | 07:02 am
- Jonathan E. Dickinson, General Manager, ARIAD Pharmaceuticals (Europe), Sàrl (Photo: Business Wire) - Business Wire 02.21.13 | 02:02 am
- ARIAD To Present At The RBC Capital Markets Healthcare Conference - Business Wire 02.19.13 | 07:02 am
- ARIAD To Present At The Leerink Swann Global Healthcare Conference - Business Wire 02.08.13 | 07:02 am
- ARIAD To Webcast Conference Call On Fourth Quarter And Year-End 2012 Financial Results - Business Wire 02.05.13 | 07:02 am
- ARIAD Announces Completion Of Public Offering - Business Wire 01.29.13 | 04:01 pm
Partner Headlines for ARIA
- Pre-Market Earnings Report for February 25, 2013 : LOW, FE, HTZ, DCI, KOS, ARIA, DDD, BGC, CTB, CWH, HL, DNDN - NASDAQ 02.22.13 | 09:02 pm
- Mid-Week Biopharma Catalyst Trades To Consider - Seeking Alpha 12.13.12 | 09:12 am
- UPDATE: Dawson James Initiates Coverage on Ariad Pharmaceuticals with Market Outperform Rating, $32 PT - Benzinga 12.07.12 | 09:12 am
- Data Published on ARIAD Candidate - Analyst Blog - Zacks 11.30.12 | 02:11 pm
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- ARIAD Seeks Ponatinib Approval - Analyst Blog - Zacks 10.02.12 | 06:10 pm
- ARIAD Partner Withdraws PMA - Analyst Blog - NASDAQ 09.19.12 | 08:09 pm
- 5 Pharmaceutical Companies With EMA Catalysts During The Next 3 - 12 Months - Part II - Seeking Alpha 09.02.12 | 08:09 am
- ARIAD Seeks EU Nod for Ponatinib - Analyst Blog - NASDAQ 08.31.12 | 10:08 pm
- ARIAD Seeks EU Nod for Ponatinib - Analyst Blog - Zacks 08.31.12 | 06:08 pm
